Skip to main content
Erschienen in: Inflammation 4/2011

01.08.2011

Effects of Simvastatin on Proinflammatory Cytokines and Matrix Metalloproteinases in Hypercholesterolemic Individuals

verfasst von: Lennart Nilsson, Per Eriksson, Pierre Cherfan, Lena Jonasson

Erschienen in: Inflammation | Ausgabe 4/2011

Einloggen, um Zugang zu erhalten

Abstract

Statins are potent lipid-lowering drugs but anti-inflammatory effects have also been suggested. Our aim was to investigate the effects of simvastatin on proinflammatory cytokines and matrix metalloproteinases (MMPs). Eighty hypercholesterolemic men were randomized to simvastatin 40 mg or placebo for 6 weeks. Simvastatin treatment significantly reduced C-reactive protein (CRP) levels while interleukin (IL)-6 levels remained unchanged. The ex vivo release of IL-1β and IL-6 was not altered by simvastatin, whereas the release of TNF-α and IL-8 increased after 6 weeks of simvastatin treatment. Similarly, the circulating levels of MMP-3 and TIMP-1 remained unaffected by simvastatin while MMP-9 increased. However, none of the effects except for the CRP reduction within the simvastatin group reached statistical significance when compared to the placebo group. Our findings are in contrast to previous in vitro and animal data and question the in vivo relevance of some of the pleiotropic effects of simvastatin.
Literatur
1.
Zurück zum Zitat Shah, P.K. 2003. Mechanisms of plaque vulnerability and rupture. Journal of the American College of Cardiology 41: 5S–22S.CrossRef Shah, P.K. 2003. Mechanisms of plaque vulnerability and rupture. Journal of the American College of Cardiology 41: 5S–22S.CrossRef
2.
Zurück zum Zitat Hansson, G.K. 2005. Inflammation, atherosclerosis, and coronary artery disease. New England Journal Medicine 352: 1685–1695.CrossRef Hansson, G.K. 2005. Inflammation, atherosclerosis, and coronary artery disease. New England Journal Medicine 352: 1685–1695.CrossRef
3.
Zurück zum Zitat Frostegård, J., A.K. Ulfgren, P. Nyberg, U. Hedin, J. Swedenborg, U. Andersson, and G.K. Hansson. 1999. Cytokine expression in advanced human atherosclerotic plaques: Dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis 145: 33–43.PubMedCrossRef Frostegård, J., A.K. Ulfgren, P. Nyberg, U. Hedin, J. Swedenborg, U. Andersson, and G.K. Hansson. 1999. Cytokine expression in advanced human atherosclerotic plaques: Dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis 145: 33–43.PubMedCrossRef
4.
Zurück zum Zitat Koenig, W., and N. Khuseyinova. 2007. Biomarkers of atherosclerotic plaque instability and rupture. Arteriosclerosis, Thrombosis, and Vascular Biology 27: 15–26.PubMedCrossRef Koenig, W., and N. Khuseyinova. 2007. Biomarkers of atherosclerotic plaque instability and rupture. Arteriosclerosis, Thrombosis, and Vascular Biology 27: 15–26.PubMedCrossRef
5.
Zurück zum Zitat Galis, Z.S., G.K. Sukhova, M. Lark, and P. Libby. 1994. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. Journal of Clinical Investigation 94: 2493–2503.PubMedCrossRef Galis, Z.S., G.K. Sukhova, M. Lark, and P. Libby. 1994. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. Journal of Clinical Investigation 94: 2493–2503.PubMedCrossRef
6.
Zurück zum Zitat Galis, Z.S., G.K. Sukhova, R. Kranzhofer, S. Clark, and P. Libby. 1995. Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases. Proceedings of the National Academy of Sciences of the United States of America 92: 402–406.PubMedCrossRef Galis, Z.S., G.K. Sukhova, R. Kranzhofer, S. Clark, and P. Libby. 1995. Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases. Proceedings of the National Academy of Sciences of the United States of America 92: 402–406.PubMedCrossRef
7.
Zurück zum Zitat Kai, H., H. Ikeda, H. Yasukawa, M. Kai, Y. Seki, F. Kuwahara, T. Ueno, K. Sugi, and T. Imaizumi. 1998. Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. Journal of the American College of Cardiology 32: 368–372.PubMedCrossRef Kai, H., H. Ikeda, H. Yasukawa, M. Kai, Y. Seki, F. Kuwahara, T. Ueno, K. Sugi, and T. Imaizumi. 1998. Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. Journal of the American College of Cardiology 32: 368–372.PubMedCrossRef
8.
Zurück zum Zitat Tayebjee, M.H., G.Y. Lip, K.T. Tan, J.V. Patel, E.A. Hughes, and R.J. MacFadyen. 2005. Plasma matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-2, and CD40 ligand levels in patients with stable coronary artery disease. The American Journal of Cardiology 96: 339–345.PubMedCrossRef Tayebjee, M.H., G.Y. Lip, K.T. Tan, J.V. Patel, E.A. Hughes, and R.J. MacFadyen. 2005. Plasma matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-2, and CD40 ligand levels in patients with stable coronary artery disease. The American Journal of Cardiology 96: 339–345.PubMedCrossRef
9.
Zurück zum Zitat Fukuda, D., K. Shimada, A. Tanaka, T. Kusuyama, H. Yamashita, S. Ehara, Y. Nakamura, T. Kawarabayashi, H. Iida, M. Yoshiyama, and J. Yoshikawa. 2006. Comparison of levels of serum matrix metalloproteinase-9 in patients with acute myocardial infarction versus unstable angina pectoris versus stable angina pectoris. The American Journal of Cardiology 97: 175–180.PubMedCrossRef Fukuda, D., K. Shimada, A. Tanaka, T. Kusuyama, H. Yamashita, S. Ehara, Y. Nakamura, T. Kawarabayashi, H. Iida, M. Yoshiyama, and J. Yoshikawa. 2006. Comparison of levels of serum matrix metalloproteinase-9 in patients with acute myocardial infarction versus unstable angina pectoris versus stable angina pectoris. The American Journal of Cardiology 97: 175–180.PubMedCrossRef
10.
Zurück zum Zitat Nilsson, L., L. Jonasson, J. Nijm, A. Hamsten, and P. Eriksson. 2006. Increased plasma concentration of matrix metalloproteinase-7 in patients with coronary artery disease. Clinical Chemistry 52: 1522–1527.PubMedCrossRef Nilsson, L., L. Jonasson, J. Nijm, A. Hamsten, and P. Eriksson. 2006. Increased plasma concentration of matrix metalloproteinase-7 in patients with coronary artery disease. Clinical Chemistry 52: 1522–1527.PubMedCrossRef
11.
Zurück zum Zitat Blankenberg, S., H.J. Rupprecht, O. Poirier, C. Bickel, M. Smieja, G. Hafner, J. Meyer, F. Cambien, L. Tiret, and AtheroGene Investigators. 2003. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 107: 1579–1585.PubMedCrossRef Blankenberg, S., H.J. Rupprecht, O. Poirier, C. Bickel, M. Smieja, G. Hafner, J. Meyer, F. Cambien, L. Tiret, and AtheroGene Investigators. 2003. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 107: 1579–1585.PubMedCrossRef
12.
Zurück zum Zitat Lubos, E., R. Schnabel, H.J. Rupprecht, C. Bickel, C.M. Messow, S. Prigge, F. Cambien, L. Tiret, T. Münzel, and S. Blankenberg. 2006. Prognostic value of tissue inhibitor of metalloproteinase-1 for cardiovascular death among patients with cardiovascular disease: Results from the AtheroGene study. European Heart Journal 27: 150–156.PubMedCrossRef Lubos, E., R. Schnabel, H.J. Rupprecht, C. Bickel, C.M. Messow, S. Prigge, F. Cambien, L. Tiret, T. Münzel, and S. Blankenberg. 2006. Prognostic value of tissue inhibitor of metalloproteinase-1 for cardiovascular death among patients with cardiovascular disease: Results from the AtheroGene study. European Heart Journal 27: 150–156.PubMedCrossRef
13.
Zurück zum Zitat Garvin, P., L. Nilsson, J. Carstensen, L. Jonasson, and M. Kristenson. 2008. Circulating matrix metalloproteinase-9 is associated with cardiovascular risk factors in a middle-aged normal population. PLoS ONE 12(3): 1774.CrossRef Garvin, P., L. Nilsson, J. Carstensen, L. Jonasson, and M. Kristenson. 2008. Circulating matrix metalloproteinase-9 is associated with cardiovascular risk factors in a middle-aged normal population. PLoS ONE 12(3): 1774.CrossRef
14.
Zurück zum Zitat Wu, T.C., H.B. Leu, W.T. Lin, C.P. Lin, S.J. Lin, and J.W. Chen. 2005. Plasma matrix metalloproteinase-3 level is an independent prognostic factor in stable coronary artery disease. European Journal of Clinical Investigation 35: 537–545.PubMedCrossRef Wu, T.C., H.B. Leu, W.T. Lin, C.P. Lin, S.J. Lin, and J.W. Chen. 2005. Plasma matrix metalloproteinase-3 level is an independent prognostic factor in stable coronary artery disease. European Journal of Clinical Investigation 35: 537–545.PubMedCrossRef
15.
Zurück zum Zitat Galis, Z.S., M. Muszynski, G.K. Sukhova, E. Simon-Morrissey, E.N. Unemori, M.W. Lark, E. Amento, and P. Libby. 1994. Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circulation Research 75: 181–189.PubMed Galis, Z.S., M. Muszynski, G.K. Sukhova, E. Simon-Morrissey, E.N. Unemori, M.W. Lark, E. Amento, and P. Libby. 1994. Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circulation Research 75: 181–189.PubMed
16.
Zurück zum Zitat Rajavashisth, T.B. 1999. Membrane type 1 matrix metalloproteinase expression in human atherosclerotic plaques. Evidence for activation by proinflammatory mediators. Circulation 99: 3103–3109.PubMed Rajavashisth, T.B. 1999. Membrane type 1 matrix metalloproteinase expression in human atherosclerotic plaques. Evidence for activation by proinflammatory mediators. Circulation 99: 3103–3109.PubMed
17.
Zurück zum Zitat Siwik, D.A., D.L.F. Chang, and W.S. Colucci. 2000. Interleukin-1b and tumor necrosis factor-a decrease collagen synthesis and increase matrix metalloproteinase activity in cardiac fibroblasts in vitro. Circulation Research 86: 1259–1265.PubMed Siwik, D.A., D.L.F. Chang, and W.S. Colucci. 2000. Interleukin-1b and tumor necrosis factor-a decrease collagen synthesis and increase matrix metalloproteinase activity in cardiac fibroblasts in vitro. Circulation Research 86: 1259–1265.PubMed
18.
Zurück zum Zitat Ferroni, P., S. Basili, F. Martini, C.M. Cardarello, F. Ceci, M. Di Franco, G. Bertazzoni, P.P. Gazzaniga, and C. Alessandri. 2003. Serum metalloproteinase 9 levels in patients with coronary artery disease: A novel marker of inflammation. Journal of Investigative Medicine 51: 295–300.PubMedCrossRef Ferroni, P., S. Basili, F. Martini, C.M. Cardarello, F. Ceci, M. Di Franco, G. Bertazzoni, P.P. Gazzaniga, and C. Alessandri. 2003. Serum metalloproteinase 9 levels in patients with coronary artery disease: A novel marker of inflammation. Journal of Investigative Medicine 51: 295–300.PubMedCrossRef
19.
Zurück zum Zitat Baigent, C., A. Keech, P.M. Kearney, L. Blackwell, G. Buck, C. Pollicino, A. Kirby, T. Sourjina, R. Peto, R. Collins, R. Simes, and Cholesterol Treatment Trialists' (CTT) Collaborators. 2005. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366: 1267–1278.PubMedCrossRef Baigent, C., A. Keech, P.M. Kearney, L. Blackwell, G. Buck, C. Pollicino, A. Kirby, T. Sourjina, R. Peto, R. Collins, R. Simes, and Cholesterol Treatment Trialists' (CTT) Collaborators. 2005. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366: 1267–1278.PubMedCrossRef
20.
Zurück zum Zitat Kwak, B.R., F. Mulhaupt, and F. Mach. 2003. Atherosclerosis: Anti-inflammatory and immunomodulatory activities of statins. Autoimmunity Review 2: 332–338.CrossRef Kwak, B.R., F. Mulhaupt, and F. Mach. 2003. Atherosclerosis: Anti-inflammatory and immunomodulatory activities of statins. Autoimmunity Review 2: 332–338.CrossRef
21.
Zurück zum Zitat Bellosta, S., D. Via, M. Canavesi, P. Pfister, R. Fumagalli, R. Paoletti, and F. Bernini. 1998. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arteriosclerosis, Thrombosis, and Vascular Biology 18: 1671–1678.PubMed Bellosta, S., D. Via, M. Canavesi, P. Pfister, R. Fumagalli, R. Paoletti, and F. Bernini. 1998. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arteriosclerosis, Thrombosis, and Vascular Biology 18: 1671–1678.PubMed
22.
Zurück zum Zitat Fukumoto, Y., P. Libby, E. Rabkin, C.C. Hill, M. Enomoto, Y. Hirouchi, M. Shiomi, and M. Aikawa. 2001. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipidemic rabbits. Circulation 103: 993–999.PubMed Fukumoto, Y., P. Libby, E. Rabkin, C.C. Hill, M. Enomoto, Y. Hirouchi, M. Shiomi, and M. Aikawa. 2001. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipidemic rabbits. Circulation 103: 993–999.PubMed
23.
Zurück zum Zitat Sukhova, G.K., J.K. Williams, and P. Libby. 2002. Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol. Arteriosclerosis, Thrombosis, and Vascular Biology 22: 1452–1458.PubMedCrossRef Sukhova, G.K., J.K. Williams, and P. Libby. 2002. Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol. Arteriosclerosis, Thrombosis, and Vascular Biology 22: 1452–1458.PubMedCrossRef
24.
Zurück zum Zitat Voleti, B., and A. Agrawal. 2006. Statins and nitric oxide reduce C-reactive protein production while inflammatory conditions persist. Molecular Immunology 43: 891–896.PubMedCrossRef Voleti, B., and A. Agrawal. 2006. Statins and nitric oxide reduce C-reactive protein production while inflammatory conditions persist. Molecular Immunology 43: 891–896.PubMedCrossRef
25.
Zurück zum Zitat Hakamada-Taguchi, R., Y. Uehara, K. Kuribayashi, A. Numabe, K. Saito, H. Negoro, T. Fujita, T. Toyo-oka, and T. Kato. 2003. Inhibition of hydroxymethylglutaryl-coenzyme a reductase reduces Th1 development and promotes Th2 development. Circulation Research 93: 948–956.PubMedCrossRef Hakamada-Taguchi, R., Y. Uehara, K. Kuribayashi, A. Numabe, K. Saito, H. Negoro, T. Fujita, T. Toyo-oka, and T. Kato. 2003. Inhibition of hydroxymethylglutaryl-coenzyme a reductase reduces Th1 development and promotes Th2 development. Circulation Research 93: 948–956.PubMedCrossRef
26.
Zurück zum Zitat Ridker, P.M., N. Rifai, M.A. Pfeffer, F. Sacks, and E. Braunwald. 1999. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 100: 230–235.PubMed Ridker, P.M., N. Rifai, M.A. Pfeffer, F. Sacks, and E. Braunwald. 1999. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 100: 230–235.PubMed
27.
Zurück zum Zitat Jialal, I., D. Stein, D. Balis, S.M. Grundy, B. Adams-Huet, and S. Devaraj. 2001. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 103: 1933–1035.PubMed Jialal, I., D. Stein, D. Balis, S.M. Grundy, B. Adams-Huet, and S. Devaraj. 2001. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 103: 1933–1035.PubMed
28.
Zurück zum Zitat Wiklund, O., L. Mattsson-Hultén, E. Hurt-Camejo, and J. Oscarsson. 2002. Effects of simvastatin and atorvastatin on inflammation markers in plasma. Journal of Internal Medicine 251: 338–347.PubMedCrossRef Wiklund, O., L. Mattsson-Hultén, E. Hurt-Camejo, and J. Oscarsson. 2002. Effects of simvastatin and atorvastatin on inflammation markers in plasma. Journal of Internal Medicine 251: 338–347.PubMedCrossRef
29.
Zurück zum Zitat März, W., K. Winkler, M. Nauck, B.O. Böhm, and B.R. Winkelmann. 2003. Effects of statins on C-reactive protein and Interleukin-6 (The Ludwigshafen Risk and Cardiovascular Health Study). The American Journal of Cardiology 92: 305–308.PubMedCrossRef März, W., K. Winkler, M. Nauck, B.O. Böhm, and B.R. Winkelmann. 2003. Effects of statins on C-reactive protein and Interleukin-6 (The Ludwigshafen Risk and Cardiovascular Health Study). The American Journal of Cardiology 92: 305–308.PubMedCrossRef
30.
Zurück zum Zitat Crisby, M., G. Nordin-Fredriksson, P.K. Shah, J. Yano, J. Zhu, and J. Nilsson. 2001. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: Implications for plaque stabilization. Circulation 103: 926–933.PubMed Crisby, M., G. Nordin-Fredriksson, P.K. Shah, J. Yano, J. Zhu, and J. Nilsson. 2001. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: Implications for plaque stabilization. Circulation 103: 926–933.PubMed
31.
Zurück zum Zitat Koh, K.K., J.W. Son, J.Y. Ahn, D.K. Jin, H.S. Kim, Y.M. Choi, and D.S. Kim. 2002. Comparative effects of diet and statin on NO bioactivity and matrix metalloproteinases in hypercholesterolemic patients with coronary artery disease. Arteriosclerosis, Thrombosis, and Vascular Biology 22: e19–e23.PubMedCrossRef Koh, K.K., J.W. Son, J.Y. Ahn, D.K. Jin, H.S. Kim, Y.M. Choi, and D.S. Kim. 2002. Comparative effects of diet and statin on NO bioactivity and matrix metalloproteinases in hypercholesterolemic patients with coronary artery disease. Arteriosclerosis, Thrombosis, and Vascular Biology 22: e19–e23.PubMedCrossRef
32.
Zurück zum Zitat Noji, Y., T. Higashikata, A. Inazu, A. Nohara, K. Ueda, S. Miyamoto, K. Kajinami, T. Takegoshi, J. Koizumi, H. Mabuchi, and Hokuriku NK-104 Study Group. 2002. Long-term treatment with pitavastatin (NK-104), a new HMG-CoA reductase inhibitor, of patients with heterozygous familial hypercholesterolemia. Atherosclerosis 163: 157–164.PubMedCrossRef Noji, Y., T. Higashikata, A. Inazu, A. Nohara, K. Ueda, S. Miyamoto, K. Kajinami, T. Takegoshi, J. Koizumi, H. Mabuchi, and Hokuriku NK-104 Study Group. 2002. Long-term treatment with pitavastatin (NK-104), a new HMG-CoA reductase inhibitor, of patients with heterozygous familial hypercholesterolemia. Atherosclerosis 163: 157–164.PubMedCrossRef
33.
Zurück zum Zitat Son, J.W., K.K. Koh, J.Y. Ahn, D.K. Jin, G.S. Park, D.S. Kim, and E.K. Shin. 2003. Effects of statin on plaque stability and thrombogenicity in hypercholesterolemic patients with coronary artery disease. International Journal of Cardiology 88: 77–82.PubMedCrossRef Son, J.W., K.K. Koh, J.Y. Ahn, D.K. Jin, G.S. Park, D.S. Kim, and E.K. Shin. 2003. Effects of statin on plaque stability and thrombogenicity in hypercholesterolemic patients with coronary artery disease. International Journal of Cardiology 88: 77–82.PubMedCrossRef
34.
Zurück zum Zitat Link, A., T. Ayadhi, M. Böhm, and G. Nickenig. 2006. Rapid immunomodulation by rosuvastatin in patients with acute coronary syndrome. European Heart Journal 27: 2945–2955.PubMedCrossRef Link, A., T. Ayadhi, M. Böhm, and G. Nickenig. 2006. Rapid immunomodulation by rosuvastatin in patients with acute coronary syndrome. European Heart Journal 27: 2945–2955.PubMedCrossRef
35.
Zurück zum Zitat Cherfan, P., A. Tompa, L.S. WikbyA, and L. Jonasson. 2007. Effects of simvastatin on human T cells in vivo. Atherosclerosis 193: 186–192.PubMedCrossRef Cherfan, P., A. Tompa, L.S. WikbyA, and L. Jonasson. 2007. Effects of simvastatin on human T cells in vivo. Atherosclerosis 193: 186–192.PubMedCrossRef
36.
Zurück zum Zitat Meisser, A., M. Cohen, and P. Bischof. 2005. Concentrations of circulating gelatinases (matrix metalloproteinase-2 and -9) are dependent on the conditions of blood collection. Clinical Chemistry 51: 274–276.PubMedCrossRef Meisser, A., M. Cohen, and P. Bischof. 2005. Concentrations of circulating gelatinases (matrix metalloproteinase-2 and -9) are dependent on the conditions of blood collection. Clinical Chemistry 51: 274–276.PubMedCrossRef
37.
Zurück zum Zitat Arnaud, C., F. Burger, S. Steffens, N.R. Veillard, T.H. Nguyen, D. Trono, and F. Mach. 2005. Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes: New evidence for direct anti-inflammatory effects of statins. Arteriosclerosis, Thrombosis, and Vascular Biology 25: 1231–1236.PubMedCrossRef Arnaud, C., F. Burger, S. Steffens, N.R. Veillard, T.H. Nguyen, D. Trono, and F. Mach. 2005. Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes: New evidence for direct anti-inflammatory effects of statins. Arteriosclerosis, Thrombosis, and Vascular Biology 25: 1231–1236.PubMedCrossRef
38.
Zurück zum Zitat Kalela, A., R. Laaksonen, T. Lehtimäki, T.A. Koivu, M. Höyhtyä, T. Janatuinen, and P. Pöllänen. 2001. Effect of pravastatin in mildly hypercholesterolemic young men on serum matrix metalloproteinases. The American Journal of Cardiology 88(173–175): A6. Kalela, A., R. Laaksonen, T. Lehtimäki, T.A. Koivu, M. Höyhtyä, T. Janatuinen, and P. Pöllänen. 2001. Effect of pravastatin in mildly hypercholesterolemic young men on serum matrix metalloproteinases. The American Journal of Cardiology 88(173–175): A6.
39.
Zurück zum Zitat Malik, J., T. Stulc, and R. Ceska. 2005. Matrix metalloproteinases in isolated hypercholesterolemia. International Angiology 24: 300–303.PubMed Malik, J., T. Stulc, and R. Ceska. 2005. Matrix metalloproteinases in isolated hypercholesterolemia. International Angiology 24: 300–303.PubMed
40.
Zurück zum Zitat Huang, C.Y., T.C. Wu, W.T. Lin, H.B. Leu, C.P. Lin, S.J. Lin, and J.W. Chen. 2006. Effects of simvastatin withdrawal on serum matrix metalloproteinases in hypercholesterolaemic patients. European Journal of Clinical Investigation 36: 76–84.PubMedCrossRef Huang, C.Y., T.C. Wu, W.T. Lin, H.B. Leu, C.P. Lin, S.J. Lin, and J.W. Chen. 2006. Effects of simvastatin withdrawal on serum matrix metalloproteinases in hypercholesterolaemic patients. European Journal of Clinical Investigation 36: 76–84.PubMedCrossRef
Metadaten
Titel
Effects of Simvastatin on Proinflammatory Cytokines and Matrix Metalloproteinases in Hypercholesterolemic Individuals
verfasst von
Lennart Nilsson
Per Eriksson
Pierre Cherfan
Lena Jonasson
Publikationsdatum
01.08.2011
Verlag
Springer US
Erschienen in
Inflammation / Ausgabe 4/2011
Print ISSN: 0360-3997
Elektronische ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-010-9227-y

Weitere Artikel der Ausgabe 4/2011

Inflammation 4/2011 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.